Phospho-MUSK (Y755) Antibody

What is the biological significance of Y755 phosphorylation in MuSK function?

Y755 represents a critical tyrosine phosphorylation site located within the activation loop of the MuSK kinase domain. This site is essential for MuSK activation and subsequent downstream signaling. When phosphorylated, Y755 contributes to the catalytic activity of MuSK, which involves transferring phosphate groups from ATP to tyrosine residues on target proteins, following the reaction: ATP + [protein]-L-tyrosine = ADP + [protein]-L-tyrosine phosphate . Phosphorylation at Y755 is closely associated with agrin-induced activation pathways and is vital for neuromuscular junction (NMJ) organization. MuSK functions as a receptor tyrosine kinase that mediates agrin's action at the postsynaptic membrane, where it colocalizes with acetylcholine receptors (AChRs) . The phosphorylation status of Y755 directly impacts MuSK's ability to participate in critical developmental and maintenance processes at the neuromuscular junction.

How does Y755 phosphorylation differ from other phosphorylation sites in MuSK?

MuSK contains multiple phosphorylation sites that work in concert but serve distinct functions. Y755 is located in the activation loop of the MuSK kinase domain, alongside other critical tyrosine residues including Y750 and Y754 . Unlike Y553, which is located in the juxtamembrane region and shows rapid, transient phosphorylation peaking at 15 minutes after agrin stimulation, Y755 phosphorylation exhibits different kinetics .

Another notable difference is seen with S751, a serine phosphorylation site that has been identified to modulate MuSK kinase activity. S751 phosphorylation increases gradually after agrin stimulation, peaking at 60 minutes and remaining stable for up to 240 minutes . This contrasts with the more immediate response pattern observed with Y755. The proximity of S751 to Y755 suggests potential interplay between these sites, with S751 phosphorylation potentially creating a novel mechanism to relieve autoinhibition of the MuSK activation loop .

What pathologies are associated with disruptions in MuSK Y755 phosphorylation?

Defects in MUSK, particularly those affecting phosphorylation at critical sites like Y755, can cause autosomal recessive congenital myasthenic syndrome (CMS) [MIM:608931] . CMS represents a group of inherited disorders of neuromuscular transmission that arise from mutations in presynaptic, synaptic, or postsynaptic proteins. MUSK mutations specifically lead to decreased agrin-dependent AChR aggregation, which is a critical step in the formation of the neuromuscular junction .

Disruptions in the phosphorylation of Y755 can impair MuSK's kinase activity, leading to compromised signal transduction at the neuromuscular junction. This can manifest as muscle weakness, fatigue, and other neuromuscular symptoms characteristic of myasthenic syndromes. Research into the specific molecular consequences of impaired Y755 phosphorylation continues to be an important area for understanding the pathophysiology of these conditions and developing potential therapeutic approaches.

What are the optimal conditions for using Phospho-MuSK (Y755) antibodies in Western blot experiments?

When using Phospho-MuSK (Y755) antibodies for Western blot analysis, researchers should follow these methodological guidelines for optimal results:

For optimal specificity, the antibody should be affinity-purified from rabbit antiserum using epitope-specific immunogen, as described for commercially available antibodies . The antibody specifically detects endogenous levels of MuSK protein only when phosphorylated at Y755, with minimal cross-reactivity to non-phosphorylated forms or other phosphorylated proteins . Researchers should store the antibody at -20°C for long-term storage and at 4°C for short-term use and frequent experiments, avoiding repeated freeze-thaw cycles that can compromise antibody performance .

How can researchers effectively validate the specificity of Phospho-MuSK (Y755) antibodies?

Validating the specificity of Phospho-MuSK (Y755) antibodies is critical for ensuring reliable research results. A comprehensive validation approach should include:

• Phosphatase Treatment Control: Treat one sample with lambda phosphatase before immunoblotting to demonstrate phosphorylation-dependent recognition.

• Peptide Competition Assay: Pre-incubate the antibody with a synthesized phospho-peptide containing the Y755 site to block specific binding.

• Knockout/Knockdown Validation: Use MuSK knockout or knockdown cell lines as negative controls to confirm antibody specificity.

• Phosphorylation-inducing Experiments: Stimulate cells with agrin (which increases MuSK phosphorylation) and compare with unstimulated cells to verify the antibody detects the phosphorylation increase.

• Cross-reactivity Testing: Test the antibody against related kinases to ensure no cross-reactivity with other phosphorylated tyrosine residues in similar sequence contexts.

Laboratories conducting validation should use positive control samples where MuSK Y755 phosphorylation is known to occur, such as agrin-stimulated C2C12 myotubes, alongside negative controls . The expected molecular weight of MuSK protein is approximately 97 kDa, which should be used as a reference when evaluating Western blot results .

What are the key differences between using Phospho-MuSK (Y755) antibodies in ELISA versus Western blot applications?

Phospho-MuSK (Y755) antibodies can be employed in both ELISA and Western blot techniques, but with important methodological distinctions:

For ELISA applications, researchers should coat plates with a capture antibody against total MuSK, then apply samples containing potentially phosphorylated MuSK, followed by detection with the Phospho-MuSK (Y755) antibody . Western blots provide the advantage of confirming the molecular weight of the detected protein (expected at 97 kDa for MuSK), which helps ensure specificity . When transitioning between these techniques, researchers should carefully optimize antibody concentrations, as the recommended dilutions differ significantly between applications (1:10,000 for ELISA versus 1:500-1:2000 for Western blot) .

How can temporal dynamics of Y755 phosphorylation be accurately measured in response to agrin stimulation?

Measuring the temporal dynamics of Y755 phosphorylation requires a methodical approach that captures the phosphorylation status at multiple time points. Based on research methodologies, a comprehensive protocol would include:

• Cell Culture Preparation: Culture C2C12 myoblasts and differentiate into myotubes for 4-5 days in differentiation medium.

• Temporal Stimulation Series: Stimulate parallel cultures with neural agrin (typically 1 nM) for varying durations (0, 5, 15, 30, 60, 120, and 240 minutes).

• Immediate Preservation: At each time point, rapidly lyse cells in buffer containing phosphatase inhibitors to preserve phosphorylation status.

• Quantitative Assessment Options:

  • Immunoprecipitation-Western Blot: Immunoprecipitate MuSK and perform Western blotting with Phospho-MuSK (Y755) antibody

  • Quantitative Mass Spectrometry: Process samples for phosphopeptide enrichment followed by LC-MS/MS analysis

  • ELISA: Develop a sandwich ELISA with capture antibodies against total MuSK and detection with Phospho-MuSK (Y755) antibody

• Data Normalization: Normalize phosphorylation signals to total MuSK protein levels to account for expression differences.

Research has demonstrated that different phosphorylation sites on MuSK show distinct temporal patterns. For instance, Y553 phosphorylation peaks early (around 15 minutes) and then decreases, while other sites like S751 show delayed phosphorylation, peaking at 60 minutes and remaining elevated for several hours . When designing experiments to study Y755 phosphorylation dynamics, researchers should consider these different kinetics and collect samples across an appropriate time range to capture both early and late phosphorylation events.

What are the interactions between Y755 phosphorylation and the nearby S751 phosphorylation site?

The interaction between Y755 and S751 phosphorylation sites represents a complex regulatory mechanism within the MuSK kinase domain. These sites are located in close proximity within the activation loop, with S751 positioned between Y750 and Y754/Y755 . Research findings suggest several important interactions:

• Sequential Phosphorylation: S751 phosphorylation typically occurs after Y553 phosphorylation, suggesting a sequential activation mechanism .

• Complementary Functions: While Y755 phosphorylation is directly linked to MuSK kinase activation, S751 phosphorylation appears to modulate this activity, particularly at non-saturating agrin concentrations .

• Autoinhibition Relief: Phosphorylation of S751 may provide a novel mechanism to relieve autoinhibition of the MuSK activation loop, potentially fostering or stabilizing MuSK kinase activation during stages with low agrin levels .

• Synergistic Effects: In experimental models, phosphomimetic mutations of S751 (S751D) increased basal MuSK tyrosine phosphorylation and enhanced responses to non-saturating agrin concentrations, suggesting that S751 phosphorylation may sensitize MuSK to activation .

• Differential Temporal Regulation: Y755 and other tyrosine residues in the activation loop typically respond rapidly to agrin, while S751 phosphorylation shows delayed kinetics, peaking at 60 minutes post-stimulation .

Researchers investigating the interplay between these sites should consider using phosphomimetic or phospho-deficient mutations (S751D/A and Y755E/F) in combination to dissect their functional relationship. These studies would help clarify whether the phosphorylation of these sites occurs interdependently or independently, and how they collectively regulate MuSK activity in different physiological contexts.

How does phosphorylation at Y755 influence MuSK's interaction with downstream signaling molecules?

Phosphorylation at Y755 serves as a critical regulatory switch that mediates MuSK's ability to interact with downstream signaling molecules. This phosphorylation event creates docking sites for signaling proteins containing phosphotyrosine-binding domains, initiating a signaling cascade that ultimately leads to AChR clustering and neuromuscular junction formation.

The key downstream interactions influenced by Y755 phosphorylation include:

Experimentally, researchers can investigate these interactions using co-immunoprecipitation studies with Phospho-MuSK (Y755) antibodies to identify binding partners specifically associated with this phosphorylation state. Additionally, proximity ligation assays can be employed to visualize interactions between phosphorylated MuSK and downstream signaling molecules in situ.

What are common causes of false negative results when using Phospho-MuSK (Y755) antibodies?

When researchers encounter false negative results with Phospho-MuSK (Y755) antibodies, several methodological factors may be responsible:

• Insufficient Phosphatase Inhibition: Phosphorylation is rapidly lost if phosphatase inhibitors are inadequate or omitted during sample preparation. Samples should be lysed in buffer containing both serine/threonine and tyrosine phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride, β-glycerophosphate).

• Suboptimal Stimulation Conditions: Ensuring proper agrin stimulation is critical. Neural agrin (Z+ variants) should be used at appropriate concentrations (0.5-1 nM) and times. Since Y755 phosphorylation follows specific temporal dynamics, sampling at inappropriate time points may miss peak phosphorylation.

• Antibody Storage Issues: Repeated freeze-thaw cycles can degrade antibody quality. Store antibodies at -20°C for long-term preservation and aliquot to avoid repeated freezing and thawing .

• Blocking Buffer Incompatibility: Using milk-based blocking buffers can introduce phosphatases that degrade phospho-epitopes. BSA-based blockers (5%) are preferred for phospho-specific antibodies.

• Insufficient Antigen Retrieval: For tissue sections, inadequate antigen retrieval can mask phospho-epitopes. Optimize heat-induced epitope retrieval methods when performing IHC.

• Low Expression Levels: MuSK expression can vary between tissues and cell types. Muscle tissues or differentiated myotubes should be used rather than undifferentiated myoblasts, which express lower levels of MuSK.

• Interfering Post-translational Modifications: Neighboring modifications may sterically hinder antibody access to the Y755 phosphorylation site, particularly considering the proximity of S751 .

To troubleshoot false negatives, researchers should include positive controls (e.g., agrin-stimulated C2C12 myotubes) alongside experimental samples and consider enriching phosphorylated proteins using immunoprecipitation prior to Western blotting to increase detection sensitivity.

How can researchers distinguish between Y755 phosphorylation and other nearby phosphorylation sites in the activation loop?

Distinguishing between Y755 phosphorylation and other nearby sites (Y750, Y754, S751) requires careful experimental design and specialized techniques:

• Site-Specific Phospho-Antibodies: Use antibodies with validated specificity for individual phosphorylation sites. Commercial antibodies like those specific for phospho-Y755 should be validated using peptide competition assays to confirm they do not cross-react with nearby phosphorylated residues .

• Phospho-Peptide Mapping: Perform tryptic digestion of immunoprecipitated MuSK followed by mass spectrometry analysis to identify and quantify phosphorylation at specific residues. This technique can definitively distinguish between modifications at different sites.

• Site-Directed Mutagenesis: Generate MuSK constructs with point mutations at individual phosphorylation sites (Y750F, Y754F, Y755F, S751A) and analyze how each mutation affects detection by phospho-specific antibodies.

• Sequential Immunoprecipitation: Perform initial immunoprecipitation with one phospho-specific antibody, followed by immunoblotting with antibodies against other phosphorylation sites to assess co-occurrence of multiple phosphorylation events.

• Phosphatase Treatment with Site Protection: Use phospho-site-specific protecting agents combined with phosphatase treatment to selectively preserve phosphorylation at one site while removing it from others.

• Temporal Analysis: Leverage the different kinetics of phosphorylation at different sites. For example, S751 shows delayed phosphorylation compared to tyrosine residues, peaking at 60 minutes after agrin stimulation .

When interpreting results, researchers should consider that these phosphorylation sites may influence each other. For instance, the phosphorylation status of S751 can affect the basal tyrosine phosphorylation level of MuSK, as demonstrated with phosphomimetic S751D mutations .

What considerations are important when designing experiments to study the effects of MuSK mutations on Y755 phosphorylation?

When investigating how MuSK mutations affect Y755 phosphorylation, researchers should incorporate these methodological considerations:

• Expression System Selection: Choose appropriate cellular models for MuSK expression. MuSK-/- muscle cells provide an ideal background for expressing mutant constructs without interference from endogenous MuSK . C2C12 myotubes are also widely used after differentiation to create a physiologically relevant environment.

• Mutation Strategy:

  • For Y755 studies: Create Y755F (phospho-deficient) mutations to prevent phosphorylation

  • For interacting sites: Consider S751A/D mutations to study interplay with Y755

  • For pathway analysis: Create mutations in upstream sites like Y553 to study sequential phosphorylation effects

• Expression Level Control: Ensure comparable expression levels between wild-type and mutant constructs. Western blotting for total MuSK should be performed to normalize phosphorylation signals to expression levels .

• Functional Readouts: Include downstream functional assays to correlate Y755 phosphorylation changes with biological outcomes:

  • AChR clustering assays using α-bungarotoxin staining

  • AChR phosphorylation measurements

  • Electrophysiological measurements at neuromuscular junctions

• Agrin Concentration Series: Test both saturating and non-saturating agrin concentrations, as certain mutations may only show phenotypes under specific stimulation conditions .

• Temporal Analysis: Examine phosphorylation at multiple time points post-stimulation (15, 30, 60, 240 minutes) to capture both early and late effects .

• Combined Mutations Analysis: Create double or triple mutations to assess the combinatorial effects of multiple phosphorylation sites.

Research has shown that phosphomimetic mutations at nearby sites (e.g., S751D) can increase basal MuSK phosphorylation and enhance responses to non-saturating agrin concentrations . These findings highlight the importance of testing mutations under various conditions to fully characterize their effects on MuSK signaling dynamics and downstream functional outcomes.

What emerging technologies could enhance the detection and functional analysis of MuSK Y755 phosphorylation?

Emerging technologies offer promising approaches for more sensitive, specific, and comprehensive analysis of MuSK Y755 phosphorylation:

• Mass Spectrometry Advancements:

  • Targeted parallel reaction monitoring (PRM) mass spectrometry for absolute quantification of specific phosphopeptides

  • Top-down proteomics approaches to analyze intact MuSK protein with multiple phosphorylation sites simultaneously

  • Ion mobility mass spectrometry to distinguish phosphoisomers with identical mass but different phosphorylation positions

• Proximity-Based Biosensors:

  • Genetically encoded FRET-based biosensors to monitor Y755 phosphorylation in real-time in living cells

  • Split luciferase complementation assays to detect interactions between phosphorylated Y755 and downstream binding partners

• Single-Molecule Techniques:

  • Super-resolution microscopy combined with phospho-specific antibodies to visualize the spatial organization of phosphorylated MuSK at the neuromuscular junction

  • Single-molecule pull-down assays to analyze stoichiometry of phosphorylation on individual MuSK molecules

• Phosphoproteomic Analysis Tools:

  • Multiplexed kinase activity profiling to understand the network of kinases regulating Y755 phosphorylation

  • Integrated computational modeling of phosphorylation cascades to predict effects of mutations on Y755 phosphorylation

• CRISPR-Based Technologies:

  • Base editing or prime editing to introduce phosphomimetic or phospho-deficient mutations at Y755 in endogenous MuSK

  • CRISPRi/a systems to modulate expression of kinases or phosphatases that regulate Y755 phosphorylation

• Antibody Engineering:

  • Development of nanobodies or synthetic binding proteins with enhanced specificity for phospho-Y755

  • BiTE (Bispecific T-cell Engager)-like molecules that simultaneously recognize phospho-Y755 and downstream effectors

These technologies could significantly advance our understanding of how Y755 phosphorylation contributes to MuSK function and neuromuscular junction development, potentially revealing novel therapeutic targets for neuromuscular disorders.

How might targeting MuSK Y755 phosphorylation lead to therapeutic approaches for neuromuscular disorders?

The central role of MuSK Y755 phosphorylation in neuromuscular junction formation and maintenance presents several promising therapeutic avenues for neuromuscular disorders:

• Small Molecule Modulators:

  • Development of compounds that enhance Y755 phosphorylation could potentially rescue defective neuromuscular transmission in congenital myasthenic syndromes

  • Kinase activators specific to MuSK could augment signaling in conditions with reduced MuSK activity

  • Phosphatase inhibitors targeting enzymes that dephosphorylate Y755 might prolong MuSK activation

• Gene Therapy Approaches:

  • Delivery of optimized MuSK variants with enhanced Y755 phosphorylation characteristics

  • CRISPR-based correction of mutations affecting the Y755 phosphorylation site or nearby regulatory residues

  • Expression of constitutively active MuSK constructs in conditions with inadequate agrin-induced signaling

• Antibody-Based Therapeutics:

  • Development of agonistic antibodies that induce MuSK dimerization and Y755 phosphorylation

  • Bispecific antibodies that simultaneously engage MuSK and Lrp4 to enhance activation

  • Antibodies blocking inhibitory interactions that normally limit Y755 phosphorylation

• Peptide Mimetics:

  • Synthetic peptides mimicking phosphorylated Y755 and surrounding sequences could potentially activate downstream signaling pathways

  • Cell-penetrating peptides protecting Y755 from dephosphorylation

• Combinatorial Approaches:

  • Targeting both Y755 and S751 phosphorylation, given their potential synergistic effects on MuSK activation

  • Combining MuSK-targeted therapies with interventions addressing other components of the agrin-Lrp4-MuSK-Dok7 pathway

Therapeutic development should consider the regulatory interplay between different phosphorylation sites. For instance, the discovery that S751 phosphorylation modulates MuSK activity suggests that targeting multiple phosphorylation events might provide more effective therapeutic outcomes than focusing on Y755 alone . Additionally, given the central role of MuSK in neuromuscular junction maintenance, these approaches could potentially benefit a wide range of conditions, from congenital myasthenic syndromes to certain forms of muscular dystrophy and even age-related neuromuscular junction deterioration.